In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies.

ABSTRACT: Antibody immunotherapy is revolutionizing modern medicine. The field has advanced dramatically over the past 40 years, driven in part by major advances in isolation and manufacturing technologies that have brought these important biologics to the forefront of modern medicine. However, the global uptake of monoclonal antibody (mAb) biologics is impeded by biophysical and biochemical liabilities, production limitations, the need for cold-chain storage and transport, as well as high costs of manufacturing and distribution. Some of these hurdles may be overcome through transient in vivo gene delivery platforms, such as non-viral synthetic plasmid DNA and messenger RNA vectors that are engineered to encode optimized mAb genes. These approaches turn the body into a biological factory for antibod

SUBMITTER: Patel A 

PROVIDER: S-EPMC7211204 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature